Squarepoint Ops LLC Decreases Stock Holdings in Taysha Gene Therapies, Inc. (NASDAQ:TSHA)

Squarepoint Ops LLC decreased its position in shares of Taysha Gene Therapies, Inc. (NASDAQ:TSHA) by 62.5% during the second quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 80,255 shares of the company’s stock after selling 133,691 shares during the period. Squarepoint Ops LLC’s holdings in Taysha Gene Therapies were worth $180,000 as of its most recent filing with the Securities & Exchange Commission.

A number of other hedge funds have also bought and sold shares of TSHA. Avoro Capital Advisors LLC increased its position in Taysha Gene Therapies by 328.2% during the first quarter. Avoro Capital Advisors LLC now owns 18,650,000 shares of the company’s stock valued at $53,526,000 after acquiring an additional 14,294,445 shares during the last quarter. StemPoint Capital LP bought a new position in Taysha Gene Therapies during the first quarter valued at $3,122,000. Bank of New York Mellon Corp bought a new position in Taysha Gene Therapies during the second quarter valued at $1,018,000. Rhumbline Advisers bought a new position in Taysha Gene Therapies during the second quarter valued at $413,000. Finally, Privium Fund Management B.V. bought a new position in Taysha Gene Therapies during the second quarter valued at $213,000. Institutional investors own 77.70% of the company’s stock.

Analysts Set New Price Targets

A number of research firms have weighed in on TSHA. JMP Securities reiterated a “market outperform” rating and set a $5.00 price objective on shares of Taysha Gene Therapies in a research report on Thursday, June 20th. Piper Sandler cut their price target on shares of Taysha Gene Therapies from $9.00 to $7.00 and set an “overweight” rating on the stock in a report on Monday, July 1st. Canaccord Genuity Group cut their price target on shares of Taysha Gene Therapies from $7.00 to $6.00 and set a “buy” rating on the stock in a report on Wednesday, August 14th. Chardan Capital restated a “buy” rating and issued a $7.00 price target on shares of Taysha Gene Therapies in a report on Tuesday, August 13th. Finally, Cantor Fitzgerald restated an “overweight” rating and issued a $7.00 price target on shares of Taysha Gene Therapies in a report on Thursday, June 20th. Eight equities research analysts have rated the stock with a buy rating, According to MarketBeat.com, the company presently has a consensus rating of “Buy” and an average price target of $6.38.

Taysha Gene Therapies Stock Up 1.5 %

Shares of Taysha Gene Therapies stock opened at $2.01 on Monday. The company has a debt-to-equity ratio of 0.35, a current ratio of 5.22 and a quick ratio of 5.22. Taysha Gene Therapies, Inc. has a 1 year low of $1.27 and a 1 year high of $4.32. The firm’s 50-day moving average is $2.13 and its two-hundred day moving average is $2.52. The stock has a market cap of $375.91 million, a price-to-earnings ratio of -4.10 and a beta of 0.40.

Taysha Gene Therapies (NASDAQ:TSHA) last released its quarterly earnings results on Monday, August 12th. The company reported ($0.09) EPS for the quarter, beating the consensus estimate of ($0.10) by $0.01. The business had revenue of $1.11 million during the quarter, compared to analyst estimates of $3.62 million. Taysha Gene Therapies had a negative net margin of 888.18% and a negative return on equity of 168.91%. During the same period in the prior year, the firm posted ($0.38) earnings per share. As a group, research analysts expect that Taysha Gene Therapies, Inc. will post -0.35 earnings per share for the current fiscal year.

About Taysha Gene Therapies

Taysha Gene Therapies, Inc, a gene therapy company, focuses on developing and commercializing adeno-associated virus-based gene therapies for the treatment of monogenic diseases of the central nervous system. It primarily develops TSHA-120 for the treatment of giant axonal neuropathy; TSHA-102 for the treatment of Rett syndrome; TSHA-121 for the treatment of CLN7 disease; TSHA-118 for the treatment of CLN1 disease; TSHA-105 for the treatment of for SLC13A5 deficiency; TSHA-113 for the treatment of tauopathies; TSHA-106 for the treatment of angelman syndrome; TSHA-114 for the treatment of fragile X syndrome; and TSHA-101 for the treatment of GM2 gangliosidosis.